The life sciences industry is built on breakthroughs and partnerships. From early-stage biotech startups to established medtech and pharma companies, success often depends on navigating complex business transactions, securing funding, protecting intellectual property, and aligning with regulatory requirements.
At Husch Blackwell, we’ve worked alongside drug manufacturers, device companies, digital health innovators, academic medical centers, CROs, and research sites to help structure deals that drive innovation while mitigating risk. The reality is, many companies—regardless of size—run into the same challenges:
- How do you structure a strategic collaboration or joint venture without jeopardizing IP or commercial rights?
- What do investors look for when evaluating life sciences companies?
- How can clinical research agreements be leveraged for long-term growth rather than becoming a regulatory bottleneck?
These aren’t just legal questions; they are business-critical issues that determine whether companies scale successfully or face costly setbacks.
That’s why our Life Sciences Transactions series will focus on real-world insights for companies at every stage—from early growth to IPO and beyond.
What to Expect in This Series
Over the next few weeks, our team—Hal Katz (transactions & healthcare regulatory), Kimberly Chew (clinical research & FDA), and Andrew Landsman & Bryan Stewart (intellectual property)—will explore key strategies and insights for navigating life sciences deals:
- Structuring the Right Deals for Growth: The do’s and don’ts of joint ventures, strategic partnerships, and commercialization agreements.
- Raising Capital in a Highly Regulated Market: What investors look for in early and late-stage funding rounds and how regulatory compliance impacts valuation.
- Intellectual Property as a Deal Asset: Why patents alone aren’t enough and how IP strategy affects M&A, licensing, and partnerships.
- Clinical Research Agreements & FDA Strategy: How regulatory requirements and trial agreements impact a company’s ability to commercialize.
- Lessons from the Field: Common mistakes life sciences companies make in transactions, funding deals, and collaborations—and how to avoid them.
Why Now?
As our team prepares to attend SXSW Interactive, we are excited to channel the energy and inspiration we gather by sharing ideas with industry leaders into this timely series. This is the perfect time to discuss how life sciences and health tech companies can position themselves for growth, secure funding, and structure deals that support long-term success.
[View source.]
